Publications by authors named "Gilberto Fronza"

Claim this Profile
T
The fading guardian: clinical relevance of TP53 null mutation in high-grade serous ovarian cancers.
Chiara M Biatta, Michele Paudice, Marco Greppi, Veronica Parrella, Alessia Parodi, Gilberto Fronza

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Fortunato Morabito, Giovanni Tripepi, Francesca Romana Mauro, Luca Laurenti, Gianluigi Reda, Gilberto Fronza

Am J Hematol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Antonella Zucchetto, Gilberto Fronza

Leukemia· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
Giuseppa De Luca, Giannamaria Cerruti, Sonia Lastraioli, Romana Conte, Adalberto Ibatici, Gilberto Fronza

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells.
Serena Matis, Anna Grazia Recchia, Monica Colombo, Martina Cardillo, Marina Fabbi, Gilberto Fronza

Blood Adv· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant p53 expression enables a partial capacity to modulate metabolism.
Paola Monti, Silvia Ravera, Andrea Speciale, Irena Velkova, Giorgia Foggetti, Gilberto Fronza

Front Genet· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Riccardo Bomben, Francesca Maria Rossi, Filippo Vit, Tamara Bittolo, Tiziana D'Agaro, Gilberto Fronza

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
Andrea Speciale, Paola Monti, Gilberto Fronza, Alberto Izzotti, Paola Menichini

Microrna· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Gilberto Fronza

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Paolo Sportoletti, Gilberto Fronza

Am J Hematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia.
Fortunato Morabito, Giovanni Tripepi, Riccardo Moia, Anna Grazia Recchia, Paola Boggione, Gilberto Fronza

Front Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol.
Fortunato Morabito, Giovanni Tripepi, Ernesto Vigna, Sabrina Bossio, Graziella D'Arrigo, Gilberto Fronza

Eur J Haematol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Gilberto Fronza

Am J Hematol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Fortunato Morabito, Giovanni Tripepi, Giovanni Del Poeta, Francesca Romana Mauro, Gianluigi Reda, Gilberto Fronza

Eur J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma.
Barbara Marengo, Alessandra Pulliero, Maria Valeria Corrias, Riccardo Leardi, Emanuele Farinini, Gilberto Fronza

J Pers Med· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Influence of a G-Quadruplex Prone Sequence on the Transactivation Potential by Wild-Type and/or Mutant P53 Family Proteins through a Yeast-Based Functional Assay.
Paola Monti, Vaclav Brazda, Natália Bohálová, Otília Porubiaková, Paola Menichini, Gilberto Fronza

Genes (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor Effects of PRIMA-1 and PRIMA-1 (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
Paola Menichini, Paola Monti, Andrea Speciale, Giovanna Cutrona, Serena Matis, Gilberto Fronza

Cells· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients.
Paola Monti, Marta Lionetti, Giuseppa De Luca, Paola Menichini, Anna Grazia Recchia, Gilberto Fronza

Sci Rep· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterogeneity of Mutations and P53 Protein Residual Function in Cancer: Does It Matter?
Paola Monti, Paola Menichini, Andrea Speciale, Giovanna Cutrona, Franco Fais, Gilberto Fronza

Front Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.
Massimo Gentile, Enrica Antonia Martino, Andrea Visentin, Marta Coscia, Gianluigi Reda, Gilberto Fronza

Blood Cancer J· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors.
Fortunato Morabito, Massimo Gentile, Paola Monti, Anna Grazia Recchia, Paola Menichini, Gilberto Fronza

Expert Opin Investig Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome.
Domenica Ronchetti, Vanessa Favasuli, Paola Monti, Giovanna Cutrona, Sonia Fabris, Gilberto Fronza

Noncoding RNA· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SLMP53-1 interacts with wild-type and mutant p53 DNA-binding domain and reactivates multiple hotspot mutations.
Ana Sara Gomes, Helena Ramos, Sara Gomes, Joana B Loureiro, Joana Soares, Gilberto Fronza

Biochim Biophys Acta Gen Subj· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P63 modulates the expression of the WDFY2 gene which is implicated in cancer regulation and limb development.
Paola Monti, Yari Ciribilli, Giorgia Foggetti, Paola Menichini, Alessandra Bisio, Gilberto Fronza

Biosci Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yeast As a Chassis for Developing Functional Assays to Study Human P53.
Paola Monti, Bartolomeo Bosco, Sara Gomes, Lucilia Saraiva, Gilberto Fronza

J Vis Exp· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis